Aziz Mottiwala - 24 Aug 2022 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Commercial Officer
Signature
/s/ Leonard M. Greenstein, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
24 Aug 2022
Net transactions value
$0
Form type
4
Filing time
26 Aug 2022, 16:25:25 UTC
Previous filing
11 Mar 2022
Next filing
17 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise $48,532 +4,416 +8.6% $10.99 55,814 24 Aug 2022 Direct F1
transaction TARS Common Stock Options Exercise $347 +772 +1.4% $0.4500* 56,586 24 Aug 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Employee Stock Option (right to buy) Options Exercise $48,532 -4,416 -29% $10.99 10,573 24 Aug 2022 Common Stock 4,416 $10.99 Direct F2
transaction TARS Employee Stock Option (right to buy) Options Exercise $347 -772 -100% $0.4500* 0 24 Aug 2022 Common Stock 772 $0.4500 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 470 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 725 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.
F2 Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020.
F3 Option granted under the Plan. 25% of the option shares vested and became exercisable on July 27, 2019 and the remaining option shares vest and become exercisable in 36 equal monthly installments thereafter.